Efficacy of tolciclate solution in patients with tinea pedis

E. C. Gomez, A. C. Huntley, Roslyn Rivkah Isseroff, J. Tanji

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Forty patients with tinea pedis were treated for six weeks in a double-blind study with a tolciclate or placebo solution. The tolciclate solution demonstrated moderate efficacy compared with placebo. The finding of positive KOH preparations in a significant number of tolciclate-treated patients with persistently negative cultures suggests that the vehicle used (polyethylene glycol-400) may not provide adequate penetration of this effective antifungal agent. No adverse effects were noted.

Original languageEnglish (US)
Pages (from-to)694-699
Number of pages6
JournalClinical Therapeutics
Volume8
Issue number6
StatePublished - 1986

Fingerprint

Tinea Pedis
Placebos
Antifungal Agents
Double-Blind Method
tolciclate

ASJC Scopus subject areas

  • Pharmacology

Cite this

Gomez, E. C., Huntley, A. C., Isseroff, R. R., & Tanji, J. (1986). Efficacy of tolciclate solution in patients with tinea pedis. Clinical Therapeutics, 8(6), 694-699.

Efficacy of tolciclate solution in patients with tinea pedis. / Gomez, E. C.; Huntley, A. C.; Isseroff, Roslyn Rivkah; Tanji, J.

In: Clinical Therapeutics, Vol. 8, No. 6, 1986, p. 694-699.

Research output: Contribution to journalArticle

Gomez, EC, Huntley, AC, Isseroff, RR & Tanji, J 1986, 'Efficacy of tolciclate solution in patients with tinea pedis', Clinical Therapeutics, vol. 8, no. 6, pp. 694-699.
Gomez, E. C. ; Huntley, A. C. ; Isseroff, Roslyn Rivkah ; Tanji, J. / Efficacy of tolciclate solution in patients with tinea pedis. In: Clinical Therapeutics. 1986 ; Vol. 8, No. 6. pp. 694-699.
@article{d434bcf757f24a42a551b48aecb726e6,
title = "Efficacy of tolciclate solution in patients with tinea pedis",
abstract = "Forty patients with tinea pedis were treated for six weeks in a double-blind study with a tolciclate or placebo solution. The tolciclate solution demonstrated moderate efficacy compared with placebo. The finding of positive KOH preparations in a significant number of tolciclate-treated patients with persistently negative cultures suggests that the vehicle used (polyethylene glycol-400) may not provide adequate penetration of this effective antifungal agent. No adverse effects were noted.",
author = "Gomez, {E. C.} and Huntley, {A. C.} and Isseroff, {Roslyn Rivkah} and J. Tanji",
year = "1986",
language = "English (US)",
volume = "8",
pages = "694--699",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - Efficacy of tolciclate solution in patients with tinea pedis

AU - Gomez, E. C.

AU - Huntley, A. C.

AU - Isseroff, Roslyn Rivkah

AU - Tanji, J.

PY - 1986

Y1 - 1986

N2 - Forty patients with tinea pedis were treated for six weeks in a double-blind study with a tolciclate or placebo solution. The tolciclate solution demonstrated moderate efficacy compared with placebo. The finding of positive KOH preparations in a significant number of tolciclate-treated patients with persistently negative cultures suggests that the vehicle used (polyethylene glycol-400) may not provide adequate penetration of this effective antifungal agent. No adverse effects were noted.

AB - Forty patients with tinea pedis were treated for six weeks in a double-blind study with a tolciclate or placebo solution. The tolciclate solution demonstrated moderate efficacy compared with placebo. The finding of positive KOH preparations in a significant number of tolciclate-treated patients with persistently negative cultures suggests that the vehicle used (polyethylene glycol-400) may not provide adequate penetration of this effective antifungal agent. No adverse effects were noted.

UR - http://www.scopus.com/inward/record.url?scp=0023024778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023024778&partnerID=8YFLogxK

M3 - Article

C2 - 3791364

AN - SCOPUS:0023024778

VL - 8

SP - 694

EP - 699

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -